Daofeng Liu

Dr. Liu joined IASO in 2021 and leads the company’s NK cell therapy product discovery efforts and novel platforms development. He has broad experience in the development, manufacturing and application of cellular therapeutics and biologics for cancer treatment. He was previously served as Sr. Director at Simcere BIC and Simnova Bio, where he was responsible for the preclinical strategies of novel NK, UCART and NKT cell therapy platforms. Prior to Simcere, Dr. Liu was a senior Scientist at NKarta, where he was group leader of preclinical investigation. Prior to joining Nkarta, Dr. Liu served as junior faculty at Baylor College of Medicine, where he was part of team for process and technology development of CAR-iNKT cell platform.

Dr. Liu received a MS and PhD in Genetics from the Institute of Genetics and Developmental Biology, Chinese Academy of Sciences. He completed postdoctoral training at the University of Southern California.